MK2870-020 (Cervical)
A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice as Second-Line or Third-Line Treatment for Participants with Recurrent or Metastatic Cervical Cancer
Description: Second-Line or Third-Line Treatment for Patients with Recurrent or Metastatic Cervical Cancer
Study Phase: Phase 3
Principal Investigator: Prof Karen Cadoo
Further information